Durvalumab 生物類似藥, PD-L1 單克隆抗體-Durvalumab Biosimilar, PD-L1 Monoclonal Antibody代理/參數/廠家-二抗-艾美捷科技有限公司

PRODUCT CENTER

二抗

產品中心

當前位置：首頁 > 產品中心 > 免疫學產品 > 二抗

背景資料: Durvalumab Biosimilar uses the same protein sequences as the therapeutic antibody durvalumab.nnPD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD1 (CD279, programmed death 1).nnDurvalumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1 (B7-H1 or CD274, programmed cell death ligand 1). Durvalumab completely blocks the binding of PDL1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.nnDurvalumab is an anticancer antibody that works to promote the antitumor response mediated by immune cells. By blocking the action of PD-L1, durvalumab exerts its anticancer effects by increasing T-cell activation, enhancing detection and ablation of tumor cells. In in vitro assays, durvalumab inhibited the activity of PD-L1 in a concentration-dependent manner. In co-engrafted human tumor and immune cell xenograft mouse models, durvalumab was effective in decreasing tumor size. Durvalumab does not mediate antibody-dependent cell-mediated cytotoxicity (ADCC).

保存建議: Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.

其他: ProMab 生物技術公司通過整合生物信息學、分子生物學、蛋白質表達、純化技術、基因克隆、微生物學和免疫學，利用新型高通量技術開發(fā)重組蛋白、抗體和工程細胞系并將其商業(yè)化。專注于免疫治療領域，特別是 CAR-T/NK 細胞技術。ProMab 還開發(fā)了一種新型的 mRNA 脂質納米顆粒（mRNA-LNP）平臺，用于即用型試劑和定制研究服務，以推進現有產品并擴展到更多的研究領域。